A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Think of your loved ones — your family, friends, people you work with, or even the people in your community. Can you name ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and ...

Heart health is important all year round and can be protected by choosing an organic diet, as supported by scientific studies ...

South Asian and East Asian adults living in the United Kingdom may have distinct trajectories to develop high blood pressure ...

Researchers found that gut microbiome composition is strongly linked to metabolic health across different life stages, with ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.